Candel Therapeutics, Inc. (NASDAQ:CADL) Insider William Garrett Nichols Sells 13,935 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction on Friday, November 29th. The shares were sold at an average price of $4.56, for a total value of $63,543.60. Following the transaction, the insider now owns 100,547 shares in the company, valued at approximately $458,494.32. This trade represents a 12.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Candel Therapeutics Price Performance

Candel Therapeutics stock traded down $0.06 during mid-day trading on Tuesday, hitting $4.51. The company’s stock had a trading volume of 596,611 shares, compared to its average volume of 524,064. The stock has a market capitalization of $146.48 million, a P/E ratio of -2.61 and a beta of -0.95. Candel Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $14.30. The stock’s fifty day moving average price is $5.50 and its two-hundred day moving average price is $6.31. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Candel Therapeutics in a research report on Monday, November 18th.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new position in Candel Therapeutics in the 2nd quarter worth about $31,000. FMR LLC acquired a new stake in shares of Candel Therapeutics during the third quarter valued at approximately $46,000. MetLife Investment Management LLC acquired a new position in Candel Therapeutics in the 3rd quarter worth approximately $87,000. Atom Investors LP purchased a new position in Candel Therapeutics during the 3rd quarter worth approximately $103,000. Finally, State Street Corp raised its stake in Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after purchasing an additional 19,207 shares during the period. 13.93% of the stock is owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.